Profiling Signaling Protein Expression, Modifications and Interactions with Multi‐dimensional Antibody Microarrays

Steven Pelech,Lambert Yue,Jeffrey White,Dirk Winkler
DOI: https://doi.org/10.1096/fasebj.30.1_supplement.lb190
2016-04-01
The FASEB Journal
Abstract:Antibody microarrays permit the sensitive and semi‐quantitative analysis of the expression, covalent modification and interactions of proteins recovered from lysates of cells and tissues. At Kinexus, we have developed high content antibody microarrays that feature pan‐and phosphosite‐specific antibodies for tracking protein kinases, phosphatases and other low abundance cell signalling proteins for their expressions, covalent modifications and interactions with multiplex detection systems. KinexTM KAM antibody microarrays with 880 printed antibodies were used to monitor protein levels, phosphorylation and interactions with combinations of different detection systems. One method involved capture of in vitro dye‐labeled proteins (e.g. with Cy3) from lysates from cells subjected to diverse treatments. Another method involved the detection of general changes in their protein phosphorylation with biotinylated pIMAGO stain and an anti‐biotin antibody that is labeled with a different dye (e.g. Cy5). Alterations in protein‐tyrosine phosphorylation were monitored with a dye‐labelled, generic phosphotyrosine‐specific PYK rabbit polyclonal antibody in a sandwich antibody microarray (SAM) format. The SAM technique was also used to explore the interactions of adapter, scaffolding and chaperone proteins with hundreds of potential target signal transduction proteins with dye‐labeled reporter antibodies for these highly interactive proteins. We used several human cancer cell lines (e.g. A431, HeLa, Jurkat, MCF7) subjected to diverse treatments (e.g. growth factors) to identify biomarkers of the actions of these agents. Reproducible results were obtained with as little as 25 μg of lysate protein, with a dynamic range of detection exceeding 6000‐fold, and a median error range for duplicates measurements of ±12%. Typically 10–15% of the proteins tracked with these arrays demonstrate perturbations exceeding 50%. More than a third of the leads from our antibody microarrays were confirmed by immunoblotting studies. The major limitation associated with validation by Western blotting was the much lower sensitivity with immunoblotting compared with antibody microarrays. We also explored the specific interactions of heat shock proteins, adapter proteins, 14‐3‐3 and calcium‐binding proteins with the antibody microarray captured lysate proteins from cancer cell lines. By combining these detection strategies, it was feasible to obtain over 7000 measurements from use of a single antibody microarray slide. The goal of our proteomics and bioinformatics studies is to use the experimental results from the application of these microarrays to map the architecture of signaling networks in a cell‐ or tissue‐specific manner. Such multi‐tiered microarray‐based analyses permit target‐directed identification of diverse regulatory protein changes in different experimental model systems with greater sensitivity, breadth, selectivity and economy when compared to any other competing proteomics methodologies. Support or Funding Information Supported by Kinexus Bioinformatics Corporation.
cell biology,biochemistry & molecular biology,biology
What problem does this paper attempt to address?